



## Nominations for Appointment to the Grants Working Group (GWG)

### Reappointment of Scientific Members to the Grants Working Group

Grants Working Group Members originally appointed in 2008-09 have terms that are now expiring or just expired. We are seeking the reappointment of the individuals listed in the table below. Their updated biographies follow. In accordance with the rules set forth by Proposition 71, reappointments should be staggered into thirds, each with a 2, 4, or 6-year term.

### **Proposed Reappointments to GWG**

Last	First	Term	Expertise
Clevers	Hans	2	Wnt Signaling & Cancer; Stem Cell Biology
Mummery	Christine	4	Pluripotency; Cardiovascular Lineages: Cellular Therapy for Cardiovascular Disease
Schöler	Hans	4	Stem Cell Pluripotency & Germline Development
Whiteside	Theresa	6	Tumor Immunology & Immunotherapy; GMP Production of Cells

### **Hans Clevers, MD, PhD**

Hans Clevers is Director of the Hubrecht Institute and Professor of Molecular Genetics in Utrecht, the Netherlands. He obtained his M.D. and Ph.D. degrees from the University of Utrecht and completed his postdoctoral work with Cox Terhorst at the Dana-Farber Cancer Institute of the Harvard University, Boston, USA. Prior to his appointment as Professor of Molecular Genetics at the Hubrecht Institute, Dr. Clevers was from 1991-2002 Professor in Immunology at the University of Utrecht.

Originally focused on T lymphocyte transcription factors, Dr. Clevers' laboratory cloned Tcf1 in 1991. With the discovery that Tcf factors are the final effectors of Wnt signaling, he changed his interests to the biology of Wnt signaling in intestinal self renewal and cancer. Dr. Clevers' laboratory has identified a series of adult tissue stem cells with the novel Lgr5 marker, currently his major focus of research.

Dr. Clevers has been a member of the Royal Netherlands Academy of Arts and Sciences since 2000 and is the recipient of several awards, including the Dutch

Spinoza Award in 2001, the Swiss Louis Jeantet Prize in 2004, the Memorial Sloan-Kettering Katharine Berkan Judd Award in 2005, the Israeli Rabbi Shai Shacknai Memorial Prize in 2006, and the Dutch Josephine Nefkens Prize for Cancer Research and the German Meyenburg Cancer Research Award in 2008. He obtained an ERC Advanced Investigator grant in 2008. He is Chevalier de la Legion d'Honneur since 2005.

### **Christine Mummery, PhD**

Christine Mummery is Chair of the Department of Anatomy and Embryology and Professor of Developmental Biology at the Leiden University Medical Center (LUMC). She studied physics at the University of Nottingham, UK and earned a Ph.D. in Biophysics at the University of London. She received a postdoctoral fellowship from the Royal Society in the UK for research at the Hubrecht Institute where she became group leader and, in 2002, Professor of Developmental Biology of the Heart for the Interuniversity Cardiology Institute of the Netherlands. In 2007 she was awarded a Harvard Stem Cell Institute/Radcliffe fellowship for a sabbatical in Harvard at Massachusetts General Hospital and the department of Disease Biophysics.

Dr. Mummery's research concerns mouse development and differentiation of mouse and human embryonic stem cells. She pioneered studies differentiating and characterizing cardiomyocytes from human embryonic stem cells and was among the first to inject them in mouse heart and assess their effect on myocardial infarction. In 2000, she introduced human embryonic stem cells into the Netherlands and subsequently received the first license to derive new lines from surplus IVF embryos. Four lines were later derived in her lab. Much of the work on these cells has concerned their differentiation to cardiomyocytes. Since moving to the LUMC in 2008, Dr. Mummery has continued her research on heart development and the differentiation of patient derived induced pluripotent human cells into the cardiac and vascular lineages. Immediate interest of her lab is on using stem cell derived cardiomyocytes and vascular cells as disease models, for drug discovery and future cardiac repair. In 2015 she became guest professor at the Technical University of Twente to develop organ-on-chip models of disease based on hiPSC.

Dr. Mummery is an elected member of the Royal Netherlands Academy of Science. She is a member of several Scientific Advisory Boards (Galapagos bv, Stem Cell Institute Leuven, the UK Pluripotent Stem Cell Initiative, the Australian Stem Cell Centre) and has written a popular book on stem cells. She is presently Editor in Chief of Stem Cell Reports (the journal of ISSCR), lead reviewer of Stem Cells, and on the Editorial Boards of Cell Stem Cell, the International Journal of Developmental Biology and Differentiation.

Dr. Mummery was an elected member of the board of ISSCR for the past 8 years and is past-president of the International Society of Differentiation. She also serves on boards of the Netherlands Heart Foundation and ZonMW (Netherlands Medical Research Council).

### **Hans Schöler, PhD**

Hans Schöler is Managing Director of the Max Planck Institute for Molecular Biomedicine and Full Professor of the Medical Faculty of the Westphalian Wilhelms-University in Münster, Germany; Adjunct Professor of the "Medizinische Hochschule Hannover"

(MHH) in Hannover, Germany; Adjunct Professor of Biochemistry at the University of Pennsylvania, Center for Animal Transgenesis and Germ Cell Research in Philadelphia, USA; Distinguished Professor at the Ulsan National Institute of Science and Technology (UNIST) and at the Konkuk University, in Seoul, South Korea.

Dr. Schöler received his Diploma in Biology and his Ph.D. in Molecular Biology at the Heidelberg University. Prior to his current position, Dr. Schöler has served as Staff Scientist at the Max Planck Institute for Biophysical Chemistry in Göttingen, Germany; Head of Research Group at Boehringer Mannheim (now Roche) in Tutzing, Germany; Head Research Center at the European Molecular Biology Laboratory and as Professor of Reproductive Physiology of the School of Veterinary Medicine at the University of Pennsylvania, USA.

Dr. Schöler long predicted that one day we would be able to change cellular fate and identity at will. This has recently been achieved, as exemplified by our ability to redirect a cell with, say, a neuronal program to one with a germ cell program, and vice versa. But the basic question that already more than a century ago fascinated scientists such as August Weismann still remains unanswered: How do somatic and germline cells differ? Dr. Schöler is interested in understanding the mammalian germline, the lineage that links one generation to the next. His two broad research areas concern pluripotent stem cells and unipotent germ cells, the two principal parts of the germline. He is intrigued by the molecular mechanisms underlying the differences between somatic and germline cells, specifically regarding differential gene regulation. Most importantly, Dr. Schöler seeks to decipher how pluripotency and totipotency are induced in differentiated cells.

Dr. Schöler has received the Robert Koch Prize in 2008, is a member of numerous professional societies, such as the German National Academy of Sciences Leopoldina, the North Rhine-Westphalian Academy of Sciences, the Academy of Sciences and Literature Mainz, the Berlin-Brandenburg Academy of Sciences and Humanities (BBAW) and of the Central Ethics Committee for Stem Cell Research.

He is a member of the editorial boards of several international journals including Cell; Cell Stem Cell; Cellular Reprogramming; The International Journal of Developmental Biology; Molecular Reproduction and Development; Stem Cells; and Stem Cells Reviews and Reports.

### **Theresa L. Whiteside, PhD**

Theresa Whiteside is Professor of Pathology, Immunology, and Otolaryngology at the University of Pittsburgh School of Medicine and the Director of the Immunologic Monitoring and Cellular Products Laboratory at the University of Pittsburgh Cancer Institute. She received a B.S. degree in Botany and a M.A. and a Ph.D. degree in Microbiology from Columbia University. Dr. Whiteside is also a diplomate of the American Board of Medical Laboratory Immunology. Following a post-doctoral fellowship and an Associate Research Scientist and Lecturer position at the New York University School of Medicine, she moved to the College of Physicians and Surgeons at Columbia University where she was a Special Fellow of the National Institutes of Health (NIH). Dr. Whiteside was then named Assistant Professor of Pathology and Associate Director of Clinical Immunopathology Laboratory at the University of Pittsburgh School of Medicine; there she rose through the faculty ranks to her current position.

Dr. Whiteside's research interests are in tumor immunology and immunotherapy with special focus on mechanisms of tumor-induced immunosuppression, cytokine networks, development of anticancer vaccines, immunology of human head and neck cancer, and the role of natural immunity in the control of cancer progression. She is a recognized expert in immune monitoring of patients with cancer. She has authored 469 peer-reviewed publications in scientific journals and 115 chapters and review articles. She is the author of a book on human tumor-infiltrating lymphocytes and co-editor of several scientific books. Over the years, she has trained over 83 post-doctoral fellows from the United States and abroad.

Dr. Whiteside has been active in national professional organizations including the following: American Association for Cancer Research (AACR) Membership Committee; AACR Program Committee; Vice President, then President of the Association of Medical Laboratory Immunologists (AMLI); and the American Society for Microbiology (ASM) Division V. She has served on numerous NIH and Department of Defense (DOD) study sections. She is a member of the Board of Scientific Counselors for the National Institute of Dental and Craniofacial Research (NIDCR). She is a member of several editorial boards including: Cellular Immunology; Clinical Immunology Immunopathology; Cancer Immunology, Immunotherapy; Clinical Cancer Research; Cancer-Therapy; Current Cancer Therapy Reviews; Journal of Immunological Methods; Current Immunology Reviews; Cancer Microenvironment; Open Cancer Journal; Open Cancer Letters; Open Cancer Review; and European Archives of Oto-Rino- Laryngology.